A61K 48/0058
Nucleic acids adapted for tissue specific expression
Official title: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
A61K48/0058 (Nucleic acids adapted for tissue specific expression) appears on 896 US grants and 2,476 published applications in this corpus.
Search patents in A61K- Granted patents
- 896
- Published applications
- 2,476
- Assignees
- 830
- Inventors
- 4,034
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 2 |
| 2002 | 7 | 12 |
| 2003 | 6 | 35 |
| 2004 | 5 | 24 |
| 2005 | 5 | 25 |
| 2006 | 7 | 33 |
| 2007 | 11 | 28 |
| 2008 | 6 | 24 |
| 2009 | 9 | 38 |
| 2010 | 10 | 26 |
| 2011 | 16 | 36 |
| 2012 | 16 | 28 |
| 2013 | 16 | 40 |
| 2014 | 26 | 42 |
| 2015 | 29 | 48 |
| 2016 | 29 | 84 |
| 2017 | 38 | 91 |
| 2018 | 47 | 122 |
| 2019 | 61 | 162 |
| 2020 | 69 | 132 |
| 2021 | 79 | 154 |
| 2022 | 65 | 197 |
| 2023 | 65 | 204 |
| 2024 | 78 | 264 |
| 2025 | 102 | 374 |
| 2026 | 85 | 251 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Methods of manufacturing microdystrophin gene therapy constructs6 Oct 2026US 12,752,021 B2REGENXBIO Inc.
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating Dravet syndrome29 Sep 2026US 12,747,452 B2New York University
- Novel regulatory cassettes for specific expression of genes in muscle stem cells8 Oct 2026US 2026/0306674 A1University of Washington
- Epigenetic repression protein therapy for rasopathies8 Oct 2026US 2026/0306675 A1Battelle Memorial Institute
- Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy8 Oct 2026US 2026/0308212 A1Research Institute At Nationwide Children's Hospital
- Gene therapy for lysosomal acid lipase deficiency (lal-d)8 Oct 2026US 2026/0308547 A1Research Institute At Nation Wide Children's Hospital
- Compositions and methods for the treatment of neuromuscular disorders8 Oct 2026US 2026/0308613 A1Astellas Gene Therapies, Inc.
Most cited
By later US patents
- AAV4 vector and uses thereof133US 6,468,524 B1The United States of America, as represented by the Secretary, Department of Health and Human Services · 2002
- Vectors for tissue-specific replication124US 5,998,205 AGenetic Therapy, Inc. · 1999
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- Recombinant AAV capsid protein95US 9,585,971 B2California Institute of Technology · 2017
- CNS targeting AAV vectors and methods of use thereof91US 9,102,949 B2University of Massachusetts · 2015